Renal cell cancer (RCC) is the thirteenth most common malignancy worldwide and the most lethal of all uro-oncological malignancies 1 . Patients with RCC rarely present with the classical triad of haematuria, loin pain and an abdominal mass; thus, patients are often diagnosed with advanced disease 2, 3 . Approximately 50% of patients present with or develop metastatic disease, which is almost always lethal 3 . In patients with the most advanced local RCC (that is, disease with vena cava involvement and venous tumour thrombus; T3b-c), recurrence rates are as high as 75% at 10 years, with a median time to progression of 9 months 4, 5 . In patients with localized disease, radical nephrectomy remains the standard treatment; however, advanced stage is associated with increased recurrence 6 . Overall, recurrence rates following nephrectomy for localized disease range from 10% to 28%, and recurrence is more common in clear cell RCC than in papillary or chromophobe subtypes [7] [8] [9] . In patients who develop a recurrence, first-line treatment knowledge on patient risk stratification, surgical and systemic therapies and provide an overview of interventions that are currently being investigated in clinical trials.
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Neoadjuvant treatment
The rationale underlying neoadjuvant therapy is to reduce the size of the primary tumour and to treat micrometastatic disease before curative surgical treatment. This approach might be necessary in patients in whom radical nephrectomy is contraindicated owing to, for example, a solitary kidney, or in an attempt to reduce an intravenous tumour thrombus to facilitate surgical excision. Neoadjuvant therapy is not currently recommended in renal cancer, as evidence from neoadjuvant trials does not support its use. Compared with adjuvant therapy, fewer trials have evaluated the use of neoadjuvant therapy, possibly because of the high cure rate of surgery and short subsequent recovery period, which limit enthusiasm among clinicians for neoadjuvant trials.
Data from a small retrospective series (n = 14 renal units) showed a median size reduction of 1.5 cm of the primary tumour following neoadjuvant sunitinib; however, the tumours were not subsequently downstaged 15 . This study included patients who were scheduled to undergo nephron-sparing surgery rather than those who had large-volume tumours or disease affecting the vena cava; thus, the indicated benefit remains unclear in this patient group. In patients with locally advanced, nonmetastatic clear cell RCC, axitinib has been shown to be safe and effective in reducing the primary renal tumour: in a phase II study (n = 24) of axitinib, a median reduction of ~28% in primary tumour diameter was observed 15 . In a small study including 12 patients with a mean tumour size of 7.1 cm, a mean reduction of 1.5 cm was seen in those treated with neoadjuvant sunitinib before nephrectomy 16 . To date, no randomized controlled trials have been published that determine the role of neoadjuvant therapy in patients with high-risk disease, including those with vena cava tumour thrombus. Thus, neoadjuvant therapy should only be given in the context of a clinical trial, with the possible exception consists of tyrosine kinase inhibitors (TKIs) 10 . The introduction of TKIs has been shown to increase median overall survival by >5 months in patients already treated with bevacizumab and interferon 11, 12 . The risk of a patient with initially localized RCC to progress to metastatic disease following radical nephrectomy can be calculated using different scoring systems and algorithms. Algorithms are an important tool in the preoperative counselling of patients, in the consideration of adjuvant treatment and in establishing appropriate patient selection in clinical trial design 5, 9, 13, 14 . Adjuvant therapy is not currently recommended in localized renal cancer, as no treatment has been shown to be of benefit; thus, standard practice comprises a watch and wait policy with radiographical surveillance followed by surgery and systemic therapies to treat the metastases 10 .
In this Perspectives, we discuss the management of patients with localized RCC who are at an increased risk of disease progression. We summarize the current Abstract | High-risk, localized renal cancer is associated with recurrence rates of up to 75% at 10 years. The outcomes of patients at this disease stage depend on optimal patient stratification, surgical management and systemic therapy selection. Current evidence does not support the use of adjuvant therapy in patients with high-risk, localized disease. During the past 12 months, the results of large, randomized-controlled trials of adjuvant tyrosine kinase inhibitor (TKI) treatment, such as ASSURE and S-TRAC, have been published, but their findings are conflicting. Whether TKIs will become standard of care in the adjuvant setting depends on the long-term data from ongoing trials. In addition, several new trials that evaluate the utility of novel immune checkpoint inhibitors in this patient group are currently recruiting. The management of renal cancer is likely to evolve at a rapid pace over the next few years and matching patients with the appropriate therapeutic regimen is likely to be a focus of future research.
of patients with marginally resectable tumours if an expert surgeon judges that a modest reduction in tumour volume might render the tumour resectable.
Surgical approach
Surgical technique can influence outcomes and improve the effectiveness of adjuvant therapy. Radical nephrectomy is the standard curative treatment for localized tumours that are not suitable for nephron-sparing surgery. Traditionally, radical nephrectomy involved the removal of the kidney, perinephric fat, Gerota fascia and the ipsilateral adrenal gland 17 . Contemporary studies suggest that this extent of radical surgery is not required 6 , and modern techniques often include sparing the adrenal gland. Routine lymphadenectomy is also not performed. However, principles of surgical cancer care suggest that oncological outcomes improve with wider excision margins and that a radical approach should be used, particularly in patients predicted to have high-risk disease.
The incidence of ipsilateral adrenal involvement is 1-5% 18 . Owing to close proximity of the adrenal gland and the upper pole of the kidney, these patients are more likely to be those with upper-pole tumours. Laterality is not a robust predictor of adrenal involvement 19 . Tumour stage is an independent predictor of adrenal involvement and tumours >6 cm are more likely to be invading the adrenal gland 20 . Disease-specific and overall survival data are similar for patients undergoing nephrectomy with or without adrenalectomy; however, ipsilateral adrenalectomy might be indicated in patients with radiological evidence of adrenal involvement, large upper pole tumours, or with venous involvement at the level of the adrenal vein 21 . Adrenalectomy might reduce the primary tumour burden, particularly in patients with upper pole tumours owing to the proximity of the adrenal gland, and, hence, improve outcomes following adjuvant therapy.
Across all stages of RCC, the incidence of incidental lymph node involvement is ~4% (that is, in patients who are cN0 on preoperative staging). In 2009, the 20-year follow-up data of the randomized phase III trial EORTC 30881 were published 22 . In 742 patients with N0M0 disease who were randomized to either radical nephrectomy or radical nephrectomy and lymph node dissection, no significant difference in disease progression or survival was found between the two groups. However, 70% UISS in estimating survival outcomes in patients with nonmetastatic clear cell RCC following nephrectomy 25 . Earlier versions of such scoring systems, for example the Memorial Sloan Kettering System and the SSIGN, include fewer variables and have been superseded by the Leibovich system and UISS.
The accuracy of clinicopathological scoring systems seems to have plateaued 26 . However, the addition of molecular markers might, in the future, enhance the ability of the Leibovich system and UISS to predict progression and response to treatment. Several molecular variables have been investigated and have shown potential as prognostic markers in patients with high-risk RCC, but currently none are routinely clinically assessed. For example, a signature consisting of expression of Ki67 and p53, endothelial expression of VEGFR 1, and epithelial expression of VEGRF 1 and VEGF D has been shown to improve prognostication in patients with nonmetastatic renal cancer 27 . In papillary RCC subtypes, intramembrane protease 3 (IMP3) has been identified as a possible marker of progression, as patients with increased IMP3 protein expression in immuno histochemistry samples might be tenfold more likely to develop metastases 28 . High expression of apoptosis inhibitor survivin and low expression of CXCR-3 protein on immunohistochemistry analysis have also been associated with disease progression after nephrectomy 29 . Increased expression of the B7 family members B7H1 (also known as PD-L1) and B7H4, which are involved in the immune response, is linked to poor prognosis in renal cancer and the corresponding pathways are being targeted therapeutically 30, 31 . The role of circulating tumour cells in renal cancer and their possible utility in prognostication remain undefined. Capture and analysis of these cells has proven difficult, but some evidence exists that circulating tumour cells can predict lymph node and distant metastases 32 . MicroRNAs are also being investigated and individual and clusters of microRNAs have been shown to predict recurrence and progression in renal cancer 33 . In general, genetic or molecular signatures will probably provide more prognostic information than single markers for patients at high-risk of disease progression following surgery, as has been shown in patients with localized or metastatic RCC [34] [35] [36] . Translational studies using banked serum and tumour tissue are a crucial part of future adjuvant trial design to enable analysis of prognostic marker panels of patients in this trial had low-risk or intermediate-risk (T1 or T2) disease and the extent of lymph node dissection was not recorded or standardized. In subgroup analysis, patients with T3 tumours had a 15% survival benefit if they had undergone lymphadenectomy (not statistically significant) 22 . A study from 2014 in 1,983 patients showed that the number of dissected nodes and extent of dissection independently affect cancer-specific survival (multivariate analysis; pT2a-b: HR 0.9, P = 0.008; pT3c-pT4a: HR 0.9, P <0.001), suggesting that extended lymphadenectomy might be useful in patients with high-risk RCC 23 . Future studies are required to confirm the role of lymphadenectomy in patients with high-risk disease; however, as with adrenalectomy, reducing the tumour burden through lymphadenectomy might increase the efficacy of adjuvant therapy.
In summary, lymphadenectomy or adrenalectomy at the time of nephrectomy is not routinely performed, but they might be valuable in select patients. The failure of recruitment into surgical RCC trials demonstrated by the poor recruitment to the cytoreductive surgery groups in the CARMENA and SURTIME studies casts doubt on the potential of future surgery-focused trials, unless we can improve engagement. In addition, we must ensure that, after randomisation of patients, clinicians are comfortable with the treatment arms patients have been assigned to 24 .
Patient prognostication
Personalized treatment and provision of the most appropriate adjuvant therapy requires accurate assessment of disease characteristics. Currently, individual patient risk is determined with nomograms, but the heterogeneity of renal cancer compromises the utility of these prognostic tools. Furthermore, several different algorithms are in use, such as the Leibovich scoring system, the stage, size, grade, and necrosis (SSIGN) score, and the UCLA integrated staging system (UISS). This diversity has led to variation in study design and limits the comparability of published data. The UISS and the Leibovich scoring system include similar variables, such as nuclear grade and presence of necrosis, but different scores are assigned, as the UISS includes performance status and symptom score. These algorithms are good estimators of overall, cancer-specific and disease-free survival (DFS) and have been used in the phase III trials of adjuvant therapy in RCC ASSURE and SORCE, respectively. The Leibovich scoring system is superior to the and ensure improved identification of those patients who are most likely to respond to new treatments.
Adjuvant therapy
In patients with localized RCC, the use of systemic therapies after surgical resection of the primary tumour (adjuvant therapy) is not supported outside of clinical trials. Current trials in this setting are currently evaluating treatment with TKIs and novel agents, such as immune checkpoint inhibitors.
Vaccines and immunotherapy agents
The high immune responsiveness of RCC led to the development of vaccines and agents designed to stimulate an immunological response against renal cancer cells, followed by their investigation in early clinical trials. Some of the initial adjuvant trials in RCC examined the roles of autologous vaccines. The vaccine Reniale was tested in a phase III adjuvant trial in patients with pT2-pT3 tumours 37 . Reniale is prepared using autologous renal cancer cells incubated with IFNγ 37 . In total, 558 patients were randomized to receive adjuvant Reniale or no adjuvant treatment. At 5-year and 70-month follow-up duration, patients who received the vaccine had a reduced risk of tumour progression (HR 1.58, 95% CI 1.05-2.37, and HR 1.59, 95% CI 1.07-2.36, respectively; P = 0.02) 37 . In another study, data from 1,267 patients treated with Reniale were retrospectively matched with those of patients who did not receive the vaccine, providing 495 matched pairs. In patients with T3 disease treated with the vaccine, 5-year and 10-year overall survival improved by 6% and 17%, respectively, in comparison with the control group, and the hazard ratio for overall survival favoured the vaccine group (HR 1.67, 95% CI 1,13-2,47; P = 0.011) 38 . advancement. In metastatic clear cell RCC, current first-line treatment consists of the TKIs sunitinib, pazopanib, or interferon plus bevacizumab, a monoclonal antibody that inhibits angiogenesis. The benefits of TKIs have been reported in metastatic disease. In a phase III trial, 750 patients were randomly assigned to receive sunitinib or IFNα 49 . Sunitinib treatment improved overall survival by almost 5 months (HR 0.821; P = 0.051). Pazopanib treatment results in similar progression-free survival (PFS) and overall survival as sunitinib, but some studies found improved quality of life outcomes and safety profile for pazopanib compared with sunitinib 50, 51 . Axitinib is an oral second-generation TKI that demonstrated improved response rates and PFS as a second-line treatment compared with the TKI sorafenib 52 . Everolimus is an mTOR inhibitor that increased PFS and significantly reduced the risk of progression (HR 0.30, 95% CI 0.22-0.40; P < 0.0001) in a randomized, controlled trial in 416 patients of whom most had undergone nephrectomy and who had already received TKIs 53 . The success of targeted therapies in the metastatic setting has supported their use in adjuvant trials (FIG. 1; TABLE 1 ). In the adjuvant setting, the first data were reported from the ASSURE study early in 2015. This large randomized trial compared 1-year adjuvant treatment with sunitinib or sorafenib versus placebo in patients with high-risk, clear cell or non-clear cell RCC 54, 55 . In 1,943 patients, the investigators found no difference in DFS (the primary end point of this study) between the three groups (median DFS 5.8 years, 6.1 years, and 6.6 years for sunitinib, sorafenib, and placebo, respectively). Overall survival was 77.9%, 80.5%, and 80.3% for sunitinib, sorafenib and placebo, respectively 55 . The discontinuation rate was 26% owing to Vitespen is an autologous cancer vaccine consisting of an endoplasmin peptide complex. Vitespen expanded the natural killer cell response and enhanced the CD8 + T-cell immune response in vitro and in vivo 39, 40 . In a randomized phase III trial in 728 patients, vitespen treatment resulted in a slight but nonsignificant reduction in disease recurrence 41 . A meta-analysis that considered three adjuvant vaccine trials involving vitespen, BCG and Reniale did not find an improvement in DFS and the use of vaccines is not currently recommended 42 . Adjuvant treatment with IFNα and IL-2 was also investigated in clinical trials. Notably, in a phase III trial, single-agent IFNα reduced the time to recurrence in patients with T3-T4 RCC with or without nodal involvement 43 .
Results of another trial suggested a protective effect of interferon treatment in patients with pN2-pN3 disease; however, only 13 patients were included in this group, and analysis of all 123 treated patients showed no overall survival benefit 44 . Adjuvant combined interferon and IL-2 treatment did not affect overall survival or DFS in another phase III trial 45 . Girentuximab is a monoclonal antibody to carbonic anhydrase 9 (CAIX), which is expressed on the surface of most clear cell RCCs and is not found in normal renal tissue 46 . In the ARISER study, 864 patients were randomized to receive girentuximab or placebo after nephrectomy. DFS did not differ between the two groups; however, patients in the girentuximab group with a high CAIX score had improved DFS of 21 months (HR 0.54, P = 0.02) 47, 48 . In summary, vaccines and immunotherapy agents in the adjuvant setting have not outperformed standard therapies such as TKIs and their use is, therefore, not recommended.
Tyrosine kinase and mTOR inhibitors
The introduction of TKIs into RCC treatment was seen as an important adverse effects, including hypertension, hand-foot reaction, fatigue, and rash 55 . Halving the dosing levels used in the initial treatment cycles lowered the discontinuation rate by almost 50%.
S-TRAC is a randomized, double-blind phase III trial comparing adjuvant sunitinib with placebo. The study included 615 patients with UISS high-risk, T3-T4 disease and results were reported in 2016 (REF. 56 ). The median DFS was 6.8 years in the treatment group versus 5.6 years in the placebo group (HR 0.76, 95% CI 0.59-0.98; P = 0.03). The follow-up duration of S-TRAC is currently too short to evaluate overall survival with meaningful results. The discontinuation rate in the sunitinib group owing to adverse events was relatively high at 28%; 48% of patients experienced grade 3 or grade 4 adverse effects compared with 16% in the placebo group 56 . In contrast to the ASSURE trial in which 79% of patients had clear cell RCC, only patients who had been diagnosed with clear-cell-subtype tumours were eligible for S-TRAC. Meta-analysis of the data from these two trials suggests a slight, but not statistically significant, benefit for DFS in patients who received adjuvant TKIs (HR 0.895, 95% CI 0.672-1.192; P = 0.450) 57 . In the ASSURE trial, 36% of patients had T1-2 disease, but their tumours were classified as grade 3-4 (REF. 56 ), so they were at the same risk level of the UISS as the patients in the S-TRAC study, which might explain the similarities in the placebo group results from both trials. In summary, analysis of ASSURE and S-TRAC does not currently support the use of adjuvant TKI therapy in patients with RCC.
Four large trials of adjuvant TKI treatment are currently ongoing. The SORCE study has recruited ~1,700 patients with intermediate-risk or high-risk interaction between T cells and tumour cells seem to restore the activity of tumour-specific T cells, leading to sustained antitumour response. Nivolumab is an IgG4 anti-PD-1 antibody that is approved for the treatment of metastatic RCC. The CheckMate 025 trial randomized 821 pretreated patients with metastatic RCC to either nivolumab or everolimus. The objective response rate was greater with nivolumab than with everolimus (25% versus 5%; OR 5.98, 95% CI 3.68-9.72; P < 0.001). The median PFS was 4.6 months for nivolumab and 4.4 months for everolimus (HR 0.88, 95% CI 0.75-1.03; P = 0.11) 64 . Grade 3 or grade 4 adverse effects were reported in 19% of patients treated with nivolumab compared with 37% of patients treated with everolimus. The European Association of Urology now recommends nivolumab or cabozantinib over the previous standard of care (TKIs or mTOR inhibitors) for patients with metastatic clear cell RCC in whom ≥1 lines of VEGF-targeted therapies have failed 10 . Evidence on the efficacy of nivolumab in papillary RCC is limited. Other antibodies targeting PD-1 or PD-L1 include atezolizumab, pembrolizumab and durvalumab.
Inhibition of the interaction via CTLA-4 between activated cytotoxic T cells and antigen-presenting cells hampers immune response downregulation and enables tumour-directed T-cell responses. The CTLA-4-targeting antibodies ipilimumab and tremelimumab are being investigated in clinical trials for RCC. In the first reported phase II trial, ipilimumab treatment had a response rate of 12.5% in patients with metastatic RCC 65, 66 . Trials of checkpoint inhibitors as neoadjuvant and adjuvant therapy in RCC are just beginning (TABLE 2) . In melanoma, (Leibovich score) clear cell or non-clear cell RCC 58 . Patients were randomized 3:3:2 to 1-year sorafenib followed by 2-year placebo, 3-year sorafenib, or 3-year placebo. SORCE completed recruitment in 2016; thus, outcome data for 3 years of treatment is some time away. PROTECT is a phase III trial that is assessing the efficacy and safety of daily pazopanib for 12 months versus placebo as an adjuvant therapy in patients with localized or locally advanced RCC after nephrectomy 59 . The trial is scheduled to complete in 2019. Early results suggest that this trial has not reached its primary end point of improving DFS 60 ; thus, the use of pazopanib 600 mg in the adjuvant setting is not supported by this trial. However, further results are yet to be published. The EVEREST trial is designed to compare recurrence-free survival (RFS) in patients treated with nine courses of 6-week everolimus versus placebo after surgery for RCC and is scheduled to complete in 2021 (REF. 61 ). ATLAS is a randomized, double-blind trial comparing 3-year, twice-daily axitinib treatment with placebo. The trial aims to recruit 700 patients and to report in 2019
Immune checkpoint inhibitors A wave of trials are currently recruiting patients with metastatic RCC to examine the utility of monoclonal antibodies against T-cell checkpoints, such as programmed cell death receptor 1 (PD-1), its ligand PD-L1, and cytotoxic T-lymphocyteassociated antigen 4 (CTLA-4). Renal tumours that express PD-L1 are more aggressive than those that do not express the marker, resulting in reduced patient survival 63 . Monoclonal antibodies that block the immuno suppressive PD-1-PD-L1 74, 75 . The underlying mechanism of this enhanced effect is unclear, but TKIs might sensitize cells and enable increased uptake of chemotherapeutic agents; however, this effect might also increase toxicity 76 . Combination of TKIs, to provide initial control, with checkpoint inhibitors, to provide a sustained response, is under investigation in patients with metastatic RCC 77 . The availability of immune checkpoint inhibitors and the enthusiasm for their use in clinical trials means that the management of renal cancer is likely to evolve at a rapid pace over the next few years. Matching the most appropriate patients with the most effective combination of treatments at the appropriate dose should be the focus of future trials. 
